指南与共识淋巴瘤白血病

Richter转化诊断、评估与研究的国际共识声明:ERIC推荐

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.
指南 / 共识 · Blood · 2025-01-01

Richter转化(RT)指慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中出现的侵袭性淋巴瘤,尽管CLL治疗进展,RT结局仍差。欧洲CLL研究倡议协调国际专家组制定共识推荐,涵盖诊断流程、活检与分子克隆关系分析、临床试验优先及早期评估RT与CLL双响应。

要点

  • 疑似RT患者应行PET-CT检查,取可及且FDG摄取最高病灶的切除活检。
  • 活检应分析侵袭性淋巴瘤并与原CLL克隆确定分子关系。
  • 因无有效标准治疗,RT患者应在临床试验中治疗并早期评估双响应。

核心结论

  • 专家组制定RT诊断、评估与研究共识推荐,以期统一临床与转化研究并改善RT患者结局。

研究设计与样本

  • 欧洲CLL研究倡议(ERIC)协调国际专家组制定共识推荐。

主要发现

  • RT患者常表现为临床快速恶化、B症状加重、乳酸脱氢酶升高和/或淋巴结迅速增大。

关键数值与推荐

  • 疑似RT患者应行PET-CT扫描。
  • 应从可及病灶取切除活检,优先选择氟脱氧葡萄糖摄取最高的病灶,并分析侵袭性淋巴瘤。
  • 应确定与原始CLL克隆的分子关系。
  • 因无有效标准治疗,患者应在临床试验中治疗。
  • 应在早期时间点评估RT与CLL的响应,试验设计应优先采用生存终点。

临床怎么用

  • 疑似RT患者应行PET-CT检查。
  • 应取可及且FDG摄取最高病灶的切除活检并分析侵袭性淋巴瘤。
  • 应确定活检标本与原始CLL克隆的分子关系。
  • 因无有效标准治疗,RT患者应在临床试验中治疗。
  • 应在早期时间点评估RT与CLL的响应,试验设计应优先采用生存终点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Richter transformation (RT) is defined as an aggressive lymphoma emerging in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). Despite novel therapeutics developed in CLL, RT is associated with poor outcomes. In light of recent progress regarding the diagnostic procedures and therapeutic concepts of RT, an international group of experts, under the coordination of the European Research Initiative on CLL, has developed consensus recommendations for clinical procedures and future research on this disease. Patients with RT typically present with a rapid clinical decline, worsening B-symptoms, elevated lactate dehydrogenase, and/or rapidly enlarging lymphadenopathy. Workup should include a positron emission tomography-computed tomography scan for patients with suspected RT. An excisional biopsy should be taken from an accessible lesion, preferably with the highest fluorodeoxyglucose avidity, and analyzed for the presence of aggressive lymphoma. The molecular relationship to the original CLL clone(s) should be defined. Because no effective standard treatment for RT exists, patients should be treated in a clinical trial. Response of both RT and CLL should be assessed at an early time point, and survival end points should be prioritized in trial design. We hope that these recommendations can help to harmonize clinical and translational research and improve outcomes for patients with RT.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kittai AS, Marchetti M, Al-Sawaf O, et al. International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations. Blood. 2025. PMID: 40239121. doi:10.1182/blood.2024028064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。